Transgene Biotek intimates BSE that SEBI Regulation 32(1) is not applicable for Q4 FY26.
Company confirms no public, rights, or preferential issue activity during the quarter ended March 31, 2026.
Filing states inability to submit XBRL filing due to system not allowing NIL entry submission.